Open AccessFlow Cytometric Bromodeoxyuridine/DNA Analysis of Hyperthermia and/or Adriamycin for Human Pancreatic Adenocarcinoma Cell Line Capan‐2
Author(s) -
Nakata Bunzo,
Chung YongSuk,
Yokomatsu Hideaki,
Sawada Tetsuji,
Kubo Toshiaki,
Kondo Yasuyuki,
Satake Katsusuke,
Sowa Michio
Publication year - 1992
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1992.tb01952.x
Subject(s) - bromodeoxyuridine , hyperthermia , flow cytometry , cell culture , cell cycle , adenocarcinoma , microbiology and biotechnology , in vitro , chemistry , pathology , biology , cell , medicine , endocrinology , cell growth , cancer , biochemistry , genetics
The effects of hyperthermia, adriamycin (ADM), and hyperthermia combined with ADM on pancreatic cancer cells were investigated from the viewpoint of cytokinetics using flow cytometric bromodeoxyuridine (BrdUrd)/DNA analysis. Human pancreatic adenocarcinoma cell line Capan‐2 was used. The untreated cells could be clearly divided into G 1 , S, G 2 M phases on contour plots of BrdUrd/DNA distribution. After heat treatment at 41–43°C, there was an accumulation of cells in the G 2 M phase which was correlated with the increase in temperature. After heat treatment at 44 or 45°C, there was marked increase in non BrdUrd‐labeled cells in the S phase. ADM caused no change in the percent of non BrdUrd‐labeled cells in the S phase, even after treatment with a concentration of 1.0 μg/ml, though that concentration of ADM caused a marked increase in the percent of cells in the G 2 M phase. After hyperthermia combined with ADM, the accumulation of the G 2 M phase increased remarkably, and was significantly higher than that after each treatment alone ( P < 0.005); however, non BrdUrd‐labeled cells in the S phase did not increase. In this study the synergistic effect of hyperthermia combined with ADM in increasing the percent of cells in the G 2 M phase could be observed by flow cytometry. The study illustrates the importance of performing in vitro flow cytometric BrdUrd/DNA analysis of combined therapy prior to the use of the combined therapy in patients.